Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Research on immunization published by scientists at Nagoya University, Department of Neurosurgery
June 4th, 2008
Fresh data on immunization are presented in the report 'Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.' According to a study from Nagoya, Japan, "The object of this study was to investigate the safety and clinical responses of immunotherapy targeting the WT1 (Wilms tumor 1) gene product in patients with recurrent glioblastoma multiforme (GBM). Twenty-one patients with WT1/HLA-A*2402-positive recurrent GBM were included in a Phase II clinical study of WT1 vaccine therapy." "In all patients, the tumors were resistant to standard therapy. Patients received intra-dermal injections of an...
Source: Vaccine Weekly (2008-06-04)
|
